These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 27476274

  • 1. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
    Francik R, Kryczyk J, Francik S.
    Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274
    [Abstract] [Full Text] [Related]

  • 2. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
    Hamilton-Craig I, Kostner KM, Woodhouse S, Colquhoun D.
    Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614
    [Abstract] [Full Text] [Related]

  • 3. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP, Jagroon IA.
    Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract] [Full Text] [Related]

  • 4. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G.
    Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
    [Abstract] [Full Text] [Related]

  • 5. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
    Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D.
    Nephrol Dial Transplant; 2000 Dec; 15(12):1993-9. PubMed ID: 11096145
    [Abstract] [Full Text] [Related]

  • 6. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
    Maiguma T, Fujisaki K, Itoh Y, Makino K, Teshima D, Takahashi-Yanaga F, Sasaguri T, Oishi R.
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):289-96. PubMed ID: 12644902
    [Abstract] [Full Text] [Related]

  • 7. [Cytolytic hepatic damage caused by ciprofibrate].
    Perault MC, Fievre JL, Dejean C, Martin A, Vandel B.
    Gastroenterol Clin Biol; 1992 Mar; 16(6-7):609. PubMed ID: 1526424
    [No Abstract] [Full Text] [Related]

  • 8. Therapeutic effects of fibrates in postprandial lipemia.
    Kolovou GD, Kostakou PM, Anagnostopoulou KK, Cokkinos DV.
    Am J Cardiovasc Drugs; 2008 Mar; 8(4):243-55. PubMed ID: 18690758
    [Abstract] [Full Text] [Related]

  • 9. [Fibrates: their prescription must be restricted].
    Béliard-Lasserre S.
    Rev Prat; 2015 Dec; 65(10):1243-4. PubMed ID: 26979011
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of effects of fibrates in patients with hypertriglyceridemia.
    Suher M, Koç E, Camur B, Sava O.
    Adv Ther; 2006 Dec; 23(5):793-8. PubMed ID: 17142215
    [Abstract] [Full Text] [Related]

  • 11. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E, Kostoula A, Elisaf M, Mikhailidis DP.
    Angiology; 2002 Dec; 53(3):273-7. PubMed ID: 12025914
    [Abstract] [Full Text] [Related]

  • 12. Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
    Raposo HF, Patrício PR, Simões MC, Oliveira HC.
    J Nutr Biochem; 2014 Jun; 25(6):669-74. PubMed ID: 24746832
    [Abstract] [Full Text] [Related]

  • 13. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
    Harlé JR, Toussirot E, Disdier P, Drancourt M, Weiller PJ.
    Rev Med Interne; 1990 Jun; 11(4):336. PubMed ID: 2096444
    [No Abstract] [Full Text] [Related]

  • 14. Fibrates and renal function.
    Gajdos M, Dzúrik R.
    Clin Nephrol; 2003 Jul; 60(1):65-6. PubMed ID: 12872864
    [No Abstract] [Full Text] [Related]

  • 15. A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
    Davidson MH.
    Cardiovasc Drugs Ther; 2009 Oct; 23(5):341-2. PubMed ID: 19844785
    [No Abstract] [Full Text] [Related]

  • 16. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
    Harvengt C.
    Acta Clin Belg; 1991 Oct; 46(2):117-9. PubMed ID: 1649529
    [No Abstract] [Full Text] [Related]

  • 17. Drug interactions with fibric acids.
    Lozada A, Dujovne CA.
    Pharmacol Ther; 1994 Aug; 63(2):163-76. PubMed ID: 7809177
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
    Okopien B, Cwalina L, Lebek M, Kowalski J, Zielinski M, Wisniewska-Wanat M, Kalina Z, Herman ZS.
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
    [Abstract] [Full Text] [Related]

  • 20. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
    Rizzo M, Berneis K.
    Curr Med Res Opin; 2007 May; 23(5):1103-11. PubMed ID: 17519077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.